Patrick Frayssinet

World Vaccine Congress Washington Speaker Interview: Dr Patrick Frayssinet

|| Dr Patrick Frayssinet, R&D Director, URODELIA

We have interviewed a few of the speakers from World Vaccine Congress Washington, taking place on 10-12 April 2017 in Grand Hyatt Washington.

This is the 1st of the interview series, stay connected for more.

Q1: The most promise opportunities in the veterinary vaccines space are?

A: One of the most promise opportunities in the veterinary vaccine space is therapeutic vaccine against pet cancer, even if it is a niche market, for two reasons. This is a very good model for therapeutic cancer vaccines for humans, and for some customized vaccines it does not need a premarket approval.

Q2: Have enough efforts been made to encourage veterinary vaccine research?

A: Veterinary vaccine research is not enough supported. Very few countries worlwide are able to invest in vaccine research and bring a vaccine to the market. It is even worse in the field of veterinary vaccine for oncologic pathologies. However the return on investment could be in human medicine as many canine or feline cancer pathologies are very similar to human.

Q3: Would you say greater veterinary vaccine research for neglected diseases is necessary?

A: Yes. I would say that the research for neglected disease could also help to develop new adjuvants able to be used in veterinary and human medicine

Q4: What are some of the neglected veterinary diseases? And what are the biggest challenges preventing more neglected veterinary disease vaccines being developed?

A: Aside from non zoonotic animal diseases representing an economic challenge for the trade of animal product, cancer vaccine is not considered as a priority in animal medicine. It is not of course a disease affecting productive livestock. Thus it is not economically a very attractive research. However investments in this field could have financial returns in human medicine as some of the cancerous pathologies of the pet are very close to their human counterparts and can constitute a very interesting model.

Q5: Please give a small overview of your talk and how it addresses some of the issues you have mentioned above

A: My presentation during the Congress will focus on the development of a kit allowing the vet to manufacture a vaccine with the proteins extracted from a tumor biopsy. This kit allows the vet to manufacture an autologous therapeutic vaccine against a particular animal tumor. The procedure to manufacture the vaccine dosis is very robust making it possible to be performed in the vet cabinet. This procedure which does not require a premarket approval permits to reduce the cost in order to fit the price requirements of the veterinary market. The mechanism of action is based on the cross priming of the patient T cells against the cancer cell by the peptides associated to the tumor heat shock proteins. Applications include canine diffuse B lymphomas, sarcomas, high grade mastocytomas, melanomas, head and neck tumors, feline sarcomas and equine melanomas.

Leave a Reply

Your email address will not be published. Required fields are marked *